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Anemia of inﬂammation (AI), also known as anemia of chronic inﬂammation or anemia of chronic disease was described over
50 years ago as anemia in association with clinically overt inﬂammatory disease, and the ﬁndings of low plasma iron, decreased
bone marrow sideroblasts and increased reticuloendothelial iron. Pathogenic features underlying AI include a mild shortening
of red cell survival, impaired erythropoietin production, blunted responsiveness of the marrow to erythropoietin, and impaired
iron metabolism mediated by inﬂammatory cytokines and the iron regulatory peptide, hepcidin. Despite marked recent advances
in understanding AI, gaps remain, including understanding of the pathogenesis of AI associated with “noninﬂammatory” or
mildly inﬂammatory diseases, the challenge of excluding iron deﬁciency anemia in the context of concomitant inﬂammation, and
understanding more precisely the contributory role of hepcidin in the development of AI in human inﬂammatory diseases.
1.Introduction
Anemia of inﬂammation (AI), also known as anemia
of chronic inﬂammation or anemia of chronic disease,
was described over 50 years ago as a normo to micro-
cytic anemia, typically of mild severity, characterized bio-
chemically by a low plasma iron, decreased total iron-
binding capacity, decreased transferrin saturation, and,
on bone marrow examination, decreased sideroblasts and
increased reticuloendothelial iron [1]. Despite the hetero-
geneity of underlying infectious, malignant and inﬂam-
matory diseases described in conjunction with this type
of anemia, there was a remarkable degree of similar-
ity in terms of the severity of the anemia, correlating
directly with the degree of inﬂammation present, and its
stability over time, features which remain characteristic
of AI today [1]. Despite advances in understanding the
underlying mechanisms leading to AI, several key clinical
issues remain, including understanding of mechanisms
of AI in “noninﬂammatory” diseases, optimal methods
for distinguishing AI from iron deﬁciency anemia, and
understanding the contributory role of various pathologic
mechanisms in individual human diseases that lead to
AI.
2.Pathophysiology ofAI
Pathogenic features underlying AI include a mild shortening
of red cell survival, impaired erythropoietin production,
blunted responsiveness of the marrow to erythropoietin,
and impaired iron metabolism [2]. Inﬂammatory cytokines,
including interleukin-1 (IL-1), tumor necrosis factor-α
(TNF-α), and interferon-γ (IFN-γ), aﬀect the diﬀerentiation
and proliferation of erythroid progenitor colony formation
in vitro [2–4]; the proapoptotic eﬀects of which have been
reversed by treatment with the TNF-inhibitor inﬂiximab
in patients with rheumatoid arthritis [5, 6]. Cytokines
and acute-phase reactants may also cause sequestration of
iron in reticulo-endothelial cells (reviewed in [4]); how-
ever, hepcidin, a key regulator of iron homeostasis, has
recently emerged as a central player in the disordered iron
metabolism seen in AI. The hepcidin gene is located on
chromosome 19 and encodes an 84aa prepropeptide which
undergoes cleavage to produce ﬁrst the circulating 60aa
prohepcidin, followed by cleavage to produce the 25aa form
of hepcidin [7]. This 25aa peptide acts via binding to the
only known mammalian cellular iron exporter, ferroportin,
leading to its internalization and degradation, with conse-
quent loss of iron export from the duodenal enterocytes2 Advances in Hematology
and reticulo-endothelial cells [8]. Hepcidin synthesis is
suppressed by erythropoiesis [9] and iron deﬁciency and
upregulated by iron overload and inﬂammation. Infusion
of IL-6 [10] or lipopolysaccharide (LPS) [11] into healthy
volunteers leads to a rapid increase in urinary hepcidin, with
concomitant decrease in serum iron levels. IL-6 upregulates
synthesis of hepcidin via signal transducer and activator
of transcription-3 (STAT-3) signaling [12]. Hepcidin levels
have been found to be elevated in patients with severe
inﬂammation when compared to healthy controls [13]. A
hepcidin transgenic mouse model replicates many of the
pathogenic features of AI, including a mild, hypochromic
anemia, sequestration of iron in the spleen, and impaired
marrow response to erythropoietin [14]. Thus, in vitro and
in animal and human models, hepcidin has been shown to
eﬀect most if not all of the iron-related changes which are
pathognomic features of AI.
3. AIin“Noninﬂammatory” States
Diagnostic features of AI in the appropriate clinical context
include characteristic iron indices associated with reduced
bone marrow sideroblasts and increased reticuloendothelial
iron [1]. In current practice, the diagnostic criteria of AI
are frequently modiﬁed to require only the presence of
anemia, the absence of overt other etiologies, and associated
peripheral blood ﬁndings of disordered iron metabolism,
such as a low serum iron with normal or elevated serum
ferritin [15]. This has led to widening of the spectrum of
clinical states associated with AI, including aging, diseases
associated with aging such as heart failure, and hospitaliza-
tion [16]. It is important to note, however, that there are
currentlynouniformperipheralbloodlaboratorycriteriafor
the diagnosis of AI.
3.1. Anemia of the Elderly. Abnormal iron indices suggestive
of AI are relatively common ﬁndings in elderly patients. In
the U.S. National NHANES III study, 20% of elderly adults
withanemiawerecharacterizedashavingAIasthesolecause
of their anemia, deﬁned as a serum iron <60mcg/dL and
no evidence of iron deﬁciency. Iron deﬁciency was in turn
deﬁned as having at least two of the following: transferrin
saturation less than 15%, serum ferritin less than 12ng/mL,
or erythrocyte protoporphyrin concentration greater than
1.24uM [17]. Aging is also associated with increased inﬂam-
mation and a mild rise in inﬂammatory markers, including
IL-6 [18, 19], and elderly patients with anemia have been
found to have higher levels of inﬂammatory markers than
elderly patients without anemia [20]. However, the degree of
inﬂammation present is mild; in one study the diﬀerences in
median levels of IL-6 and C-reactive protein (CRP) between
anemic and nonanemic elderly patients were relatively small
(2.5 versus 1.4pg/mL and 4.9 versus 2.7mg/L, resp.) [21].
Can AI-type pathophysiology exist in the absence of
associated clinically evident inﬂammatory disease? This
question has been studied in elderly patients. In an early
report, 5 elderly patients without underlying inﬂammatory
disease presented with a microcytic, hypochromic anemia,
low serum iron levels, and increased bone marrow iron [22].
In ferrokinetic studies, these patients were found to have low
iron absorption, normal iron utilization (incorporation of
infused iron into red cells), and decreased reutilization of
iron (incorporation of iron from infused hemoglobin into
red cells). These ﬁndings of low serum iron, low iron binding
capacity, high serum ferritin, and increased bone marrow
iron in elderly patients in the absence of malignant or
inﬂammatory diseases were termed “primary defective iron-
reutilization syndrome” [23]. Interestingly, treatment with
testosterone enanthate led to improvements in hemoglobin,
redcellmass,andironreutilization.Inafollow-upstudy,two
similar patients were described [23]. Treatment with danazol
in both patients resulted in an increases in hemoglobin,
serum iron, percent transferrin saturation, and decreased
ferritin, suggesting that treatment led to release of previ-
ously sequestered reticulo-endothelial iron. These results are
intriguing and suggest both that disordered iron metabolism
can develop in the absence of overt inﬂammatory disease,
and also that androgen therapy, at least in this small
patient sample, corrected the underlying defect. Androgens
have been shown to increase erythropoietin levels [24]a n d
hematopoietic stem cell cycling [25]; however it seems more
likely that an unrelated mechanism led to improvement in
the anemia and iron homeostasis in these cases. It would also
be interesting to assess whether milder biochemical evidence
of disordered iron metabolism, that is, a mild normocytic
normochromic anemia with less dramatically abnormal iron
indices, had similar ferrokinetic ﬁndings. It is possible that
t h eu s eo fm o r es e n s i t i v em a r k e r so fi n ﬂ a m m a t i o ns u c ha s
the high sensitivity CRP would isolate a subset of patients
without overt inﬂammatory disease who nonetheless had
ﬁndings consistent with AI.
3.2. Anemia of Heart Failure. AI as deﬁned by iron indices
is also common in patients with congestive heart failure.
In one study, 85 of 148 (57%) anemic outpatients with
congestive heart failure had AI [26]. Those with AI had
higher levels of inﬂammatory markers, including IL-6 and
TNF-α, compared to levels found in previously reported
healthysubjects,supportingthediagnosticcriteria.However,
in another study in anemic hospitalized patients with more
advanced heart failure, 27 of 37 (73%) had iron deﬁciency
as diagnosed by the gold standard of absent iron on bone
marrow aspirate, despite the group having a mean ferritin
of 75 ± 59.1ng/mL [27]. Thus, using a serum ferritin cutoﬀ
level of >50ng/mL may be too restrictive in excluding iron
deﬁciency anemia in patients with heart failure. The ﬁndings
from this study highlight the dilemma of distinguishing
iron deﬁciency anemia from AI, which remains a frequent
clinical challenge despite the availability of tests such as the
soluble transferrin receptor (sTfR), a marker of increased
erythropoiesis and iron deﬁciency [28].
3.3. Identifying Iron Deﬁciency in Patients with AI. Recent
work suggests that measuring hepcidin levels may have
future utility in distinguishing the two disorders. In a rat
model of chronic inﬂammation and iron deﬁciency anemia,Advances in Hematology 3
hepatic hepcidin mRNA was suppressed in controls with
iron deﬁciency alone, elevated in rats with inﬂammation
alone, and suppressed in rats with combined inﬂammation
and iron deﬁciency [29]. Serum hepcidin levels followed
a similar but less distinct pattern. Rats with inﬂammation
had signiﬁcantly less uptake of orally administered iron
compared with both control rats and rats with combined
inﬂammation and iron deﬁciency. In the same study, human
patients were designated as having anemia of inﬂammation
in combination with iron deﬁciency if they had anemia, an
associated inﬂammatory disease, and a transferrin satura-
tion <16%, serum ferritin of <100mcg/mL and sTfR/log
ferritin >2. Serum hepcidin levels were signiﬁcantly higher
in patients with inﬂammation alone than in those with
either iron deﬁciency alone or combined iron deﬁciency
and inﬂammation. Consistent with these results, in human
duodenal biopsy samples, mRNA expression of ferroportin
wasincreasedinthosewithcombinedinﬂammationandiron
deﬁciency compared to those with inﬂammation alone. In
another study utilizing a mouse model of sepsis and pro-
longed organ dysfunction, inﬂammation-induced increase
in hepatic hepcidin mRNA was suppressed by phlebotomy,
and,toalesserextent,byerythropoietinadministration[30].
These results suggest that severe iron deﬁciency exerts a
dominant eﬀect over inﬂammation with regard to regulation
of hepcidin in vivo, and furthermore, that hepcidin levels,
if validated for clinical use, may be of utility in conﬁrming
or excluding iron deﬁciency in the presence of concomitant
inﬂammation.
3.4. Anemia of Chronic Kidney Disease (CKD). Anemia
of CKD is another “noninﬂammatory” disease in which
inﬂammation may actually play a prominent role in the
development of anemia. The pathogenesis of anemia in CKD
is multifactorial and predominately driven by impaired ery-
thropoietin production; however inﬂammation negatively
impacts erythropoiesis and is associated with resistance to
erythropoietic therapy [31, 32]. Several recent studies have
measuredhepcidinlevelsinpatientswithCKDinaneﬀortto
clarify the contributory role of hepcidin and disordered iron
metabolism in anemia in this disease. Ashby et al. measured
plasma hepcidin (by immunoassay) in healthy controls and
patients with chronic kidney disease both oﬀ (44 patients)
and on (94 patients) hemodialysis [33]. Although hepcidin
levels did not correlate strongly with ferritin levels in
patients on hemodialysis (felt by the authors to be related
to intravenous iron supplementation in this group), in those
not on hemodialysis, hepcidin levels did correlate strongly
with ferritin levels, consistent with upregulation of hepcidin
in relation to increased iron. In addition, hepcidin levels
were negatively correlated with erythropoietin dose, and fell
slightly in patients who were initiated on erythropoietin
therapy. There was no correlation between hepcidin levels
and markers of inﬂammation (CRP or IL-6) in either
group.Interestingly,therewasanegativecorrelationbetween
hepcidin and worsening renal function. Plasma growth
diﬀerentiation factor-15 (GDF15) levels, which are elevated
in thalassemia major and inhibit hepdcidin synthesis [34],
did not appear to negatively regulate hepcidin in this setting,
consistent with results in normal volunteers treated with
low-dose recombinant human erythropoietin [35]. Weiss
et al. measured serum hepcidin as well as iron indices in
20 patients on hemodialysis and found that hepcidin levels
correlated positively with serum iron, ferritin, transferrin
saturation, and negatively with reticulocyte count, but not
with markers of inﬂammation, including serum IL-6, trans-
forming growth factor-β (TGF-β), or CRP [36]. However,
the patients had relatively low levels of inﬂammation, with
meanCRPlevelsofonly0.7mg/dL.Similarly,Tomosugietal.
measured hepcidin levels using a semiquantitative surface-
enhanced laser desorption ionization time of ﬂight mass
spectrometry (SELDI-TOF MS) assay and found that while
serum hepcidin-25 levels correlated well with IL-6 levels
in patients with acute infection, there was no correlation
between hepcidin and IL-6 in patients receiving dialysis
without additional associated inﬂammatory disease [37].
Zaritsky et al. found in adults with chronic kidney disease
stages 2 to 4, ferritin, soluble transferrin receptor levels and
glomerularﬁltrationrate(GFR)weredirectlycorrelatedwith
serum hepcidin levels. When pediatric patients with CKD
stages 2–5 were included in a multivariate analysis, high
resolution CRP also correlated with serum hepcidin levels
[38]. Thus, these studies, taken together, suggest that in
patients with CKD without additional inﬂammatory disease,
hepcidin is regulated predominately by iron status, and to a
lesserextentbyerythropoiesis,andevenlessbyinﬂammation
and thus may not play a prominent contributory role in the
anemia associated with CKD.
4.HepcidinLevelsin
Inﬂammatory BowelDisease
Measurements of hepcidin levels in inﬂammatory bowel dis-
ease (IBD) have also yielded interesting results. In one study,
six pediatric patients with active Crohn’s disease (deﬁned
as an IL-6 level >5pg/mL) had poor absorption of a single
dose of oral iron and high urinary hepcidin levels (mean
295.3ng/mg creatinine) compared to ten patients with
relatively inactive Crohn’s disease (with IL-6 levels ≤5pg/mL
and mean urinary hepcidin levels 31.22ng/mg creatinine).
Thus, patients with active disease had a markedly higher
hepcidin levels than those with quiescent disease, consistent
with the hepcidin model of AI. Interestingly, hemoglobin
levels were similar in both groups (mean 11.7 and 11.6g/dL
in active and inactive disease, resp.). Although this was
possibly due to the small number of patients studied, the
a b s e n c eo fad i ﬀerence in hemoglobin level despite markedly
diﬀerent hepcidin levels also raises the possibility that ele-
vatedhepcidindoesnotdrivetheanemiainthisdisease,even
when active. Surprisingly, in another study in 61 patients
with inﬂammatory bowel disease (mean age 44 years), serum
hepcidin levels, as measured by radioimmunoassay, were
signiﬁcantly lower in those with IBD compared to healthy
controls. In this study, iron deﬁciency anemia was deﬁned
as the presence of a low serum iron (<10.6umol/L) and low
serumferritin(<15ug/L). AI wasdeﬁned as anemia with low4 Advances in Hematology
serum iron and normal ferritin level. Although the directly
contrasting results between these two studies may potentially
be explained by diﬀerences in urine versus serum hepcidin
assays, an alternative explanation is that patients with IBD
with a serum ferritin above 15 may still be iron deﬁcient
and have suppressed hepcidin synthesis. Regardless, these
contrasting results highlight the need for further studies to
more accurately delineate the contributory role of hepcidin
in the development of AI in IBD.
In summary, despite marked recent advances in under-
standing AI, gaps remain, including understanding the
pathogenesis of AI associated with “noninﬂammatory” or
mildlyinﬂammatorydiseases,thechallengeofexcludingiron
deﬁciency anemia in the context of concomitant inﬂam-
mation, and understanding more precisely the contributory
role of hepcidin in the development of AI in human
inﬂammatory diseases.
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